Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter
induction study. The purpose of this study is to evaluate the efficacy and safety of oral
BT-11 induction compared to placebo in subjects with moderate to severe CD. Approximately 100
sites will participate from Europe and the United States.